Ray lenalidomide treatment of elderly threaten myelodysplastic syndrome in low-risk group of 22 patients1.docVIP

 PAGE \* MERGEFORMAT 7 Ray lenalidomide treatment of elderly threaten myelodysplastic syndrome in low-risk group of 22 patients1 Of: Yang Li Wei Yan Lin Sun Jingnan Dan Xiumin [Keywords:] Ray lenalidomide; myelodysplastic syndrome Myelodysplastic syndrome (MDS) is a group originated in hematopoietic stem / progenitor cells in hematologic malignancy to ineffective hematopoiesis and has translated into high-risk acute leukemia characterized. Peripheral blood expressed as a series or a series of more than persistent reduction of blood cells, bone marrow dysplasia phenomenon occurs, there may be a typical cytogenetic changes (1). MDS occurred in patients over 60 years of age, the conventional chemotherapy drugs and to stimulate hematopoiesis in patients with MDS for the most ineffective in recent years, many the treatment of newly developed drugs have been listed or MDS undergoing clinical trials, the U.S. Food and Drug Administration (FDA) has approved the mine lenalidomide, azacytidine, to the West coast of the three drugs used in his treatment of MDS , which is mainly used in mine lenalidomide 5q syndrome, but the latest NCCN MDS treatment guidelines 2009 edition has included mine lenalidomide in low-risk group 1 endangered MDS treatment options (2 to 4). our department from March 2009 began to threaten in the IPSS low-risk score of 1 has 22 cases of economic conditions, the first attempt to apply in the domestic Indian-Ray lenalidomide treatment, clinical observation of the data now reported the following summary. 1 Materials and Methods 1.1 The objects were 22 patients in our department, and bone marrow smears of peripheral blood, bone marrow biopsy, bone marrow mononuclear cell chromosome, diagnosed with MDS, including 10 males and 12 females, median age 65 (60 ~ 83) years of age; average time from diagnosis to treatment of 7.95 (from 0 to 120) months; IPSS score of 0 points in 7 cases, 8 cases of 0.5 points, 1.0 points in 7 cases; WHO classifi